12月2日 - ** 制药商Amneal Pharmaceuticals AMRX.O股价盘前上涨1.2%至12.45美元
** 该公司称，美国 FDA 批准了其广泛使用的哮喘药硫酸沙丁胺醇吸入气雾剂的仿制药。
** 在该公司的仿制药获得批准之前，美国食品和药物管理局还批准了梯瓦公司TEVA.TA治疗哮喘的QVAR吸入器--AMRX的仿制药。
** 该公司称，两项批准标志着该公司在复杂的呼吸系统药物市场取得了进展
** 截至上次收盘，该公司股价年累计上涨约 55
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.